Sanofi to deploy Median image interpretation, management solution
Median Technologies has signed a contract with Sanofi for the interpretation and end-to-end management of medical images in a Phase II study on small cells lung cancer.
Under the contract, Median will employ its LMS platform at all 65 investigator and independent review sites.
The aim of the project is to reduce reading variability and discordance issues in image interpretation, which are thought to impact clinical trial outcomes.
Using Median LMS, the sites will be able to conduct RECIST 1.1 criteria-based evaluations, while the end-to-end image management will be carried out through Median CTIS.
The real-time electronic imaging data transfer from investigator sites to independent review sites will allow the independent reviews to be processed faster and with a more efficient management of queries on missing or erroneous data.
Median Technologies Business Development vice president Jerome Windsor said their solutions increase the accuracy of data interpretation and also create new perspectives for pathology follow up, benefiting the patients.
Related Insight
Suppliers Directory
HighTable- Gathering and Sharing Expertise
HighTable helps you gather and share expertise. In a world where everyone's connected, it's surprisingly difficult to find insights from people who know what they’re talking about. Would you rather go straight to the source or search the internet for hours?
Automation > IT & Software > Suppliers
ANSYS - Pharmaceutical Engineering Simulation Software
ANSYS, Inc. develops and distributes engineering simulation software capable of reproducing, with great accuracy, numerous processes involved in pharmaceutical, biomedical and biotechnology applications.
Automation > IT & Software > Suppliers
Accuri Cytometers - Flow Cytometry
Accuri Cytometers, Inc. was founded to address a compelling need: life scientists love the rapid analysis capability of flow cytometers, but too few have a flow cytometer in their lab.
Automation > IT & Software > Suppliers
PharmARC - Analytic Solutions for Efficient Commercialisation of Drugs and Medical Products
PharmARC is a 100% life sciences focused company that provides analytic solutions for efficient commercialization of drugs and medical products. We enable our customers to make informed decisions related to their sales and marketing strategies, and implementation, yielding better ROI.
Automation > IT & Software > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
IT & Software Intelligence
Efficient Drug Registration Process Based on Document Management
Published by Infotehna Group
Automation > IT & Software > White Papers
eCTDmanager™ Suite: Comprehensive Submission Management Solution
Published by EXTEDO
Automation > IT & Software > White Papers
Oncology and Clinical Trials in the 21st Century
Published by BioClinica
Automation > IT & Software > White Papers
Understanding Pasteurisation and Sterilisation Processes
Published by Tecnosoft
Automation > IT & Software > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.